Showing results (31-40 of 229) with videos related to
Sort By:
Pageof 23
International Journal of Mass Spectrometry|March 18, 2014
Evaluation of ion mobility-mass spectrometry for determining the isomeric heterogeneity of oligosaccharide-alditols derived from bovine submaxillary mucinHongli Li, Brad Bendiak, Kimberly Kaplan, et al.Annals of Hematology|January 30, 2015
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphomaMyron S Czuczman, Stephen Kahanic, Andres Forero, et al.Cancer Causes & Control : CCC|March 6, 2009
Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypesLenka Goldman, Sameera Ezzat, Nadia Mokhtar, et al.Clinical Lymphoma, Myeloma & Leukemia|April 3, 2019
Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and OutcomesTherese Andraos, Zeina Ayoub, Loretta Nastoupil, et al.International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.Journal of Pediatric Orthopedics|December 14, 2018
Radiation Prophylaxis for Hip Salvage Surgery in Cerebral Palsy: Can We Reduce the Incidence of Heterotopic Ossification?Eric Davis, Kathryn Williams, Travis H Matheney, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Effect of hepatitis C virus infection in patients with cancer: addressing a neglected populationHarrys A Torres, Parag Mahale, Boris Blechacz, et al.Leukemia & Lymphoma|January 5, 2024
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphomaMichael Dickinson, Joaquin Martinez-Lopez, Etienne Jousseaume, et al.Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.Leukemia & Lymphoma|July 25, 2013
Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphomaQasiem J Nasser, Margaret L Pfeiffer, Jorge Romaguera, et al.Pageof 23